Icon
+91 94997 68112
Login Register

Relistor - (12mg/0.6ml; Solution, Subcutaneous)

Methylnaltrexone bromide SALIX Pharma
12mg/0.6ml; Solution, Subcutaneous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
 None
Indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has been insufficient
Yes
***** ** *** ***** ** **** **** ** *** ****/*.*** & ***/*.*** ******** ********* **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, **** *** *** ************ *********. ** ****** **** **** ***** ******* ** ***** ****. ******* **** (*******), *** **** ***** **** ** **** **** ******* ** ****/*.*** & ***/*.*** ******** ********* *** *** ************ *********. ** ********** ******* ***** & ****(*******) ***** ***** ****** '*** ** ***** *** ********* **** **** ** *** ******** *** ***** ****** *** *, ****. ** ******** ** ********* **** ******* ** ****** '***. *****, ******* ******* **** ***** ** ******* *****. **** (*******) ** *** ***** ** **** **** ** **** ******** ***** ****** **** ******* ’*** ******, ’*** ******, ’*** ******, ’*** ******, *** ’*** ******. ** ****** **** **** **** (*******) ****** ** *** ****. ****: ***** ******* ** $**** ******** ***** *********** ** ********* ** *** ****, ******* *** ********* ********. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***) ********* *** ****** *** *******. *** ******* ******** ****** ****** ** **** *** ***** ** **** *** ***** **** ***** *** *** **** ** ***** ******. ***** ******* ********** **** ***** ***** ***** *** ** ****** '***. *** ***** ** ********** *** *** ***** *** ** *** ****** *** ******* ****** ** ** ** *** **** **** (***** **** ******* **** ******* *** ****** ** *** ****)
Relistor Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
***** ******* ******* *** ** ** ******* ******* *** ********* *** ********* *** ********* **** *** ******
******* ******* ******* *** ** ** ******* ******* *** ********* *** ********* *** ********* *** *********
*** ****** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** *** **, **** ******* ***** *** ** ** ** ****** '*** ********* ******** ** *** ****
******* ** \ ** *** **, **** ******* ***** *** ** ** ** ****** '*** ******** ** *** **, ****
*** ****** ** \ ** *** **, **** ******* **** ** *** **, ****
  1. *** *, **** : ***** ******** ******* ***** *** **** ** *** ********* ** **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  2. *** **, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
  3. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** *** ********* ** **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****.
  4. *** **, **** : ***** ******** ******* ***** *** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  5. *** *, **** : ******* ***** * **** ******** ******* ** ******** ***** ** **.
  6. *** *, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
  7. *** **, **** : ******* ***** * **** ******* *** ** *** ***** **** ** *** ********* ** **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****.
  8. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  9. *** **, **** : ******* ******* **** * ********** *** ******* ********* **** *** ********* ** ***** *** ****** ****** *** ******* ****** *** **, ****.
  10. *** **, **** : **** & ******* ******** ******* ***** ***** **** *** ***** ******** ******* **** ******* ’*** ******, ’*** ******, ’*** ******, ’*** ******, *** ’*** ******
  11. *** **, **** : ******** ***** ***** ** ******* ** ***** ** ******* *** ******* ***** *** ****(*******) ***** ***** ***** ****** '***- *** *, **** ** ***** *** ********* ** ***** *** *******. ***** *** ******* ******** *** ******** ** ******* *******.
  12. *** *, **** : ** ******** ** ********* **** ******* ** ****** '***
  13. *** **, **** : ******* ******* **** ***** ** ******* *****.
  14. *** **, **** : ********** ******** **** *** & ***** *** ******** ********** *** *** *** ******* ** ****.
  15. *** **, **** : ******* *** ********* ********. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***)
  16. *** *, **** : ***** ****** ******** ****** ****** ********* *** **** ** ******.
  17. *** **, **** : ****** ****** **** ***** ****** ** ******* '***, '***, '***, '***, '***, '***, '*** *** '***.
  18. *** **, **** : ****** ****** ******* ********** **** ***** ****** ** ******* *****

Relistor - (150 mg; Tablet, Oral)

Methylnaltrexone bromide SALIX Pharma
150 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indications for RELISTOR: Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation
Yes
**** ** ***. **** ***** * **** ** ** *** ******* *** *** *********. ** ****** **** **** **** ******* ** **** ****. *****, ***** ***** **** ******* (***** **, ****) ****** ** ***** *** ********* ** ****. **, ** ******** **** **** **** ****** **** ******* ***** ***** **, ****(*.* ***** ****** ** '*** ******)
Relistor Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
**** ******* ******** *** ** *** **** ** ** ******** *** ** *** ******** *** ** *** ******** *** ** *** ******** *** ** *** ******** *** ** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ** **** *, **** ******* ***** ****** ** ** ********* ******** ******* *** **** *** *** ****
  1. *** *, **** : ****** ****** ***** * **** ******* **** ** ******* '***, '***(**** **, ****) *** '***, '***, '*** (***** **, ****)
  2. *** *, **** : ****** ****** ***** * **** ******* **** ** ******* '***, '*** (**** **, ****)
  3. *** **, **** : ****** ****** ***** * **** ******* **** ** ****** ******** (***** **, ****)
  4. **** **, **** : ***** ***** **** ******* (***** **, ****) ****** ** ***** *** ********* ** ****. **** ******** **** ******** ** **.
  5. *** *, **** : ****** ****** **** * ******** *** ** *** **** (*******) **** ******* '***, '***, '***, '***, '***, *** '***.
  6. *** **, **** : **** (*******) ********* *** ** ****** ******* ****** ******.
  7. *** **, **** : ****** ****** *** **** (*******) ******* ********** **** ****** '*** ** ******* *****.

Relistor - (8mg/ 0.4ml; Solution, Subcutaneous)

Methylnaltrexone bromide SALIX Pharma
8mg/ 0.4ml; Solution, Subcutaneous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
 None
Indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, where response to laxative therapy has been insufficient
Yes
***** ** ******** *** ***** ** **** *** **** *** *** ********* ********. ******* *** **** ***** **** **. ***** **** ***** *** ******* **** ** ****** '*** ** **, *** ******** *** ******** ** ******* ***** ***** ** ******. ** *********** ** ********* ********* ******** ** ***** *******. *****, ******* ******* **** ***** ** ******* *****. ** *** ****, ******* *** ********* ********. ********* ** ****** ** **** ****** *** ******* ***** ********** ** '*** ******. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***)
Relistor Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
***** *******/*** ********* ******* *******/*** ********* ******* *******/*** ********* **** ** **, ******** ** ** ******* *******/*** *********
******* ******* ******* *** ** ** ******* ******* ******* ******* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** *** **,**** ******* ***** *** ** ** ********* ******** ** *** ****
******* ** \ ** *** **, **** ******* ***** *** ** ** ******** *** ****** *** **, ****
  1. *** **, **** : * **** ** ** *****
  2. *** **, **** : ***** ******** ******* ***** *** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  3. *** *, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
  4. *** *, **** : ******* ******** ******* ***** *** **** ****** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****, '*** (*** **, ****)
  5. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****, '*** (*** **, ****)
  6. *** **, **** : ***** *** ********* ********
  7. *** **, **** : ******** ***** ***** ** ******* ** ***** ** ******* *** ******* ***** *** ****(*******) ***** ***** ***** ****** '***- *** *, **** ** ***** *** ********* ** ***** *** *******. ***** *** ******* ******** *** ******** ** ******* *******.
  8. *** *, **** : ** ******** ** ********* **** ******* ** ****** '***
  9. *** **, **** : ******* ******* **** ***** ** ******* *****.
  10. *** **, **** : ******* *** ********* ********. ********* ** ****** ** **** ****** *** ******* ***** ********** ** '*** ******. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***)

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.